Abstract
Prostate cancer that no longer responds to hormonal manipulation can be defined as hormone-refractory prostate cancer. Until recently, there has been no standard chemotherapeutic approach for hormone-refractory prostate cancer. The major benefits of chemotherapy in the treatment of the disease are palliative in nature, in terms of reduction of pain and use of analgesics and improvement of performance status, as followed in the most recent trials. Phase III studies are necessary to better evaluate the efficacy of the different regimens, because several old studies suffer for methodological deficits. There is a promising activity of new drug combinations, such as vinca alkaloids and taxanes. Phase I and II trial are testing combinations of classic chemotherapeutic agents and biologic drugs, and the first results appear interesting. In this article, recent advances in the treatment of hormone-refractory prostate cancer using chemotherapeutic regimens are critically reviewed.
| Original language | English |
|---|---|
| Pages (from-to) | 349-360 |
| Number of pages | 12 |
| Journal | Tumori |
| Volume | 89 |
| Issue number | 4 |
| Publication status | Published - Jul 2003 |
Fingerprint
Keywords
- Chemotherapy
- Hormone-refractory prostate cancer
- Treatment
ASJC Scopus subject areas
- Cancer Research
Cite this
Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. / Di Lorenzo, Giuseppe; Autorino, Riccardo; De Laurentiis, Michele; Bianco, Roberto; Lauria, Rossella; Giordano, Antonio; De Sio, Marco; D'Armiento, Massimino; Bianco, Angelo Raffaele; De Placido, Sabino.
In: Tumori, Vol. 89, No. 4, 07.2003, p. 349-360.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease
AU - Di Lorenzo, Giuseppe
AU - Autorino, Riccardo
AU - De Laurentiis, Michele
AU - Bianco, Roberto
AU - Lauria, Rossella
AU - Giordano, Antonio
AU - De Sio, Marco
AU - D'Armiento, Massimino
AU - Bianco, Angelo Raffaele
AU - De Placido, Sabino
PY - 2003/7
Y1 - 2003/7
N2 - Prostate cancer that no longer responds to hormonal manipulation can be defined as hormone-refractory prostate cancer. Until recently, there has been no standard chemotherapeutic approach for hormone-refractory prostate cancer. The major benefits of chemotherapy in the treatment of the disease are palliative in nature, in terms of reduction of pain and use of analgesics and improvement of performance status, as followed in the most recent trials. Phase III studies are necessary to better evaluate the efficacy of the different regimens, because several old studies suffer for methodological deficits. There is a promising activity of new drug combinations, such as vinca alkaloids and taxanes. Phase I and II trial are testing combinations of classic chemotherapeutic agents and biologic drugs, and the first results appear interesting. In this article, recent advances in the treatment of hormone-refractory prostate cancer using chemotherapeutic regimens are critically reviewed.
AB - Prostate cancer that no longer responds to hormonal manipulation can be defined as hormone-refractory prostate cancer. Until recently, there has been no standard chemotherapeutic approach for hormone-refractory prostate cancer. The major benefits of chemotherapy in the treatment of the disease are palliative in nature, in terms of reduction of pain and use of analgesics and improvement of performance status, as followed in the most recent trials. Phase III studies are necessary to better evaluate the efficacy of the different regimens, because several old studies suffer for methodological deficits. There is a promising activity of new drug combinations, such as vinca alkaloids and taxanes. Phase I and II trial are testing combinations of classic chemotherapeutic agents and biologic drugs, and the first results appear interesting. In this article, recent advances in the treatment of hormone-refractory prostate cancer using chemotherapeutic regimens are critically reviewed.
KW - Chemotherapy
KW - Hormone-refractory prostate cancer
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=0142073762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0142073762&partnerID=8YFLogxK
M3 - Article
C2 - 14606635
AN - SCOPUS:0142073762
VL - 89
SP - 349
EP - 360
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 4
ER -